Overview
Lanka Hospitals operates a 367-bed multi-speciality tertiary hospital, supported by diagnostics, pharmacies and related healthcare services in Sri Lanka. Its latest quarter showed a widening gap between operating performance and reported profit: core operating earnings softened, while finance, tax, associate and foreign-exchange items below the operating line materially lifted net profit.
Price performance
LHCL closed at LKR 112 on 2026-08-14. The share gained 4.7% over three months and 8.7% over six months, while the ASPI fell 5.6% and 9.2% over the same periods. Over one year, LHCL rose 32.1% against the index's 9.3% gain, although it fell 4.9% in one month while the ASPI gained 1.0%.
The price sits 10.4% below its 52-week high and 31.0% above its low, placing it at 67.1% of its range. Recent volatility was 17.0% below its own one-year level, while 20-day volume was 56.2% below its 60-day average, indicating quieter recent trading rather than lower market risk.
Valuation
LHCL trades at 10.53 times earnings, below the healthcare median P/E of 11.24, while its 1.63 P/B is modestly above the sector median of 1.52. The latest audited ROE was 12.7%, so the premium to sector book value is not supported by an unusually high reported return on equity. No sector percentile was supplied.
The 2.7% dividend yield is above the sector median of 1.7%, and the payout direction has improved: dividend per share rose from LKR 1.50 in FY2024 to LKR 3.00 in FY2025. The latest payout represented 28.2% of earnings, with 3.55 times dividend cover.
News and sentiment
Coverage was broadly normal, with one article in the last 30 days against a baseline of 1.2, and four material articles over 90 days. All four were neutral, covering board and management changes, trading disclosures and the FY2025 cash dividend rather than operating developments.
The FY2025 dividend was confirmed in two payments: LKR 2.00 went ex on 2026-01-06 and LKR 1.00 on 2026-06-03. No undated corporate action is pending in the supplied data.
Financials
Revenue grew 7.0% year-on-year to LKR 3.82 billion in the quarter ended 2026-06-30, but operating profit fell 10.8% to LKR 399 million. Gross margin improved from 42.9% to 44.1%, ranking 4th of seven comparable June quarters, while operating margin narrowed from 12.5% to 10.4%, also ranking 4th of seven.
Net profit rose 60.2% to LKR 717 million, lifting net margin from 12.5% to 18.8%. Net margin ranked 2nd of seven comparable June quarters, among its best readings. The below-line result added LKR 319 million to operating profit, so the reported profit increase was not matched by operating earnings.
Equity increased from LKR 14.63 billion at June 2025 to LKR 16.37 billion at June 2026. Reported share counts also differ materially, from 267.2 million at December 2025 quarterly reporting to 223.7 million in the FY2025 annual filing, so per-share comparisons require care; the supplied corporate-action record does not identify the cause.
Risks
The main risk is profit quality: twelve-month cash conversion was only 0.25 times to 2026-06-30, meaning the recent profit record did not arrive in operating cash at the same rate. This matters because net profit grew faster than operating profit.
The annual balance sheet remains liquid, with a 2025 current ratio of 4.15 and free cash flow of LKR 1.70 billion. Interest cover was strong at 36.01 times, but gearing was not reported on the annual balance-sheet data. Quarterly total debt stood at LKR 844 million at June 2026, alongside cash of LKR 1.02 billion.
Sri Lankan healthcare coverage is also placing greater emphasis on hospital cybersecurity governance. Sector-wide energy-driven inflation reached 7.3%, creating a cost environment that could pressure margins, although the supplied data does not isolate its effect on LHCL.
Outlook
The next company-specific event is the filing for the quarter ending 2026-09-30. As at 2026-08-16, exchange timing data places publication between 2026-11-07 and 2027-01-07; that filing will show whether operating earnings recover after the latest quarter's decline or whether net profit continues to rely on below-line support.
Lower Sri Lankan interest-rate expectations and abundant liquidity form a more supportive financing backdrop as at 2026-08-16, while elevated inflation remains a cost risk. The available data cannot determine whether either backdrop will materially change LHCL's hospital margins.